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Background: SARS-CoV-2 is straining health care systems globally. The burden on hospitals during the pandemic could be
reduced by implementing prediction models that can discriminate patients who require hospitalization from those who do not.
The COVID-19 vulnerability (C-19) index, a model that predicts which patients will be admitted to hospital for treatment of
pneumonia or pneumonia proxies, has been developed and proposed as a valuable tool for decision-making during the pandemic.
However, the model is at high risk of bias according to the “prediction model risk of bias assessment” criteria, and it has not been
externally validated.
Objective: The aim of this study was to externally validate the C-19 index across a range of health care settings to determine
how well it broadly predicts hospitalization due to pneumonia in COVID-19 cases.
Methods: We followed the Observational Health Data Sciences and Informatics (OHDSI) framework for external validation
to assess the reliability of the C-19 index. We evaluated the model on two different target populations, 41,381 patients who
presented with SARS-CoV-2 at an outpatient or emergency department visit and 9,429,285 patients who presented with influenza
or related symptoms during an outpatient or emergency department visit, to predict their risk of hospitalization with pneumonia
during the following 0-30 days. In total, we validated the model across a network of 14 databases spanning the United States,
Europe, Australia, and Asia.
Results: The internal validation performance of the C-19 index had a C statistic of 0.73, and the calibration was not reported
by the authors. When we externally validated it by transporting it to SARS-CoV-2 data, the model obtained C statistics of 0.36,
0.53 (0.473-0.584) and 0.56 (0.488-0.636) on Spanish, US, and South Korean data sets, respectively. The calibration was poor,
with the model underestimating risk. When validated on 12 data sets containing influenza patients across the OHDSI network,
the C statistics ranged between 0.40 and 0.68.
Conclusions: Our results show that the discriminative performance of the C-19 index model is low for influenza cohorts and
even worse among patients with COVID-19 in the United States, Spain, and South Korea. These results suggest that C-19 should
not be used to aid decision-making during the COVID-19 pandemic. Our findings highlight the importance of performing external
validation across a range of settings, especially when a prediction model is being extrapolated to a different population. In the
field of prediction, extensive validation is required to create appropriate trust in a model.
(JMIR Med Inform 2021;9(4):e21547) doi: 10.2196/21547
KEYWORDS
external validation; transportability; COVID-19; prognostic model; prediction; C-19; modeling; datasets; observation;
hospitalization; bias; risk; decision-making
Introduction
Background
The novel coronavirus SARS-CoV-2, which causes COVID-19,
is quickly spreading throughout the world and burdening health
care systems worldwide [1]. Numerous prediction models are
being developed and released to the public to aid
decision-making during the pandemic [2]. Many of these models
aim to inform people of their risk of developing severe outcomes
due to COVID-19 [3-5]. A recent systematic review found that
all the then-published models suffered from high risk of bias
along with one or more limitations, including small data sets
used to develop the models and lack of external validation [2].
The COVID-19 vulnerability (C-19) index [5] is an example of
a prognostic model developed to identify people susceptible to
severe outcomes during COVID-19 infection. The model is
potentially valuable because it aims to predict hospitalization
risk in the general population [2]. At the time of the study, a
paper on the model was available as a preprint [5], and the model
itself was publicly available at a website [6]. The C-19 index
aims to predict which patients will require hospitalization due
to pneumonia (or proxies for pneumonia) within 3 months. The
model was developed using retrospectively collected Medicare
data (patients aged 65 years or older) that did not include
patients with COVID-19.
Objectives
In this paper, we aim to show the importance of external
validation and demonstrate the feasibility, during times of
urgency, of using a collaborate network for this purpose. We
chose to demonstrate this with the C-19 index because it is
available as a commercial product to the public, prior to being
peer-reviewed, as a model that can predict COVID-19 severity,
but it has not undergone any external validation. It is unknown
whether this model is currently being used for medical
decision-making, but it has been advertised as a decision-making
tool. However, the process illustrated in this paper and the
lessons learned are applicable to any COVID-19 prediction
model. Furthermore, the C-19 index model was developed using
non–COVID-19 data, and there is no guarantee that a model
trained on Medicare patients who do not have COVID-19 will
perform similarly or even adequately in patients with
COVID-19. Research has shown that there is high risk of bias
for a model that lacks external validation [7]. In addition, it is
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recommended to assess the knowledge of a model’s
reproducibility and transportability before it is used clinically
[8]. Models must be reliable, as poor predictions can be
detrimental to decision-making [2].
The Observational Health Data Science and Informatics
(OHDSI) collaboration is a group of researchers who are
collaborating to develop best practices for analyzing
observational health care data [9]. OHDSI has developed a
framework that enables timely validation of prediction models
across a large number of data sets worldwide [10]. The OHDSI
network currently contains large COVID-19 cohorts from the
United States, Europe, and Asia. In this study, we aim to
demonstrate the importance of performing external validation
of a model before its predictions can be trusted. As a case study,
we chose to investigate the predictive performance of the C-19
index when applied to COVID-19 data from databases across
the world. This study provides information about the suitability
of using the C-19 index model to aid decision-making during
the COVID-19 pandemic.
Methods
Existing C-19 Index Models
Three models were developed in the C-19 index paper [5]. The
simplest model was a logistic regression with a limited number
of predictors: age, sex, hospital usage, 11 comorbidities, and
their age interactions. The other two models were less
parsimonious gradient boosting machines with more than 500
variables. Only one of these gradient boosting machine models
was reported. Withholding a model results in noncompliance
with the TRIPOD (Transparent Reporting of a Multivariable
Prediction Model for Individual Prognosis or Diagnosis)
statement [11] and makes external validation impossible. In this
paper, we chose to evaluate the simple logistic regression model,
recognizing that COVID-19 prediction models are urgently
needed worldwide and that parsimonious models are more
readily implemented across health care settings.
Data Source
Electronic medical records (EMRs) and administrative claims
databases from primary care and secondary care systems
containing patients from Australia, Japan, the Netherlands,
Spain, South Korea, and the United States were analyzed in a
distributed network, as detailed in Multimedia Appendix 1,
Table S1. Of these data sets, 5 contained COVID-19 cases and
9 did not. All data sets used in this paper were mapped into the
OHDSI Observational Medical Outcomes Partnership Common
Data Model (OMOP-CDM) [12]. The OMOP-CDM was
developed to provide researchers with diverse data sets with a
standard database structure. This enables analysis code and
software to be shared among researchers, which facilitates
external validation of prediction models. Deidentified or
pseudonymized data were obtained from routinely collected
records from clinical practice. Analyses were performed using
the following databases: the Australia Electronic Practice–Based
Research Network (AU-ePBRN) (linked primary and secondary
care database from Australia); Japanese Medical Data Center
(JMDC) (Japanese claims); Integrated Primary Care Information
(IPCI) (primary care EMR from the Netherlands); Information
System for Research in Primary Care (SIDIAP) (primary care
EMR from Spain); Ajou University School of Medicine
(AUSOM) and Health Insurance Review and Assessment
(HIRA) (EMR and claims database, respectively, from South
Korea); Commercial Claims and Encounters (CCAE),
ClinFormatics, Medicare (MDCR), Medicaid (MDCD) (US
claims databases), Optum EHR, Department of Veterans Affairs
(VA), Columbia University Irving Medical Center (CUIMC)
and Tufts Medical Center Research Data Warehouse (TRDW)
(US EMRs). All analyses were conducted locally in a distributed
network in which the analysis code was sent to participating
sites and only aggregate summary statistics were returned, with
no sharing of patient-level data between organizations.
Consent to Publish
Each site obtained institutional review board approval for the
study or used deidentified data; therefore, the study was
determined not to be human subject research. Informed consent
was not necessary at any site.
Participants
The purpose of the C-19 index is to identify which patients with
COVID-19 are more likely to require hospitalization due to
severe complications. The C-19 index model was developed
using non–COVID-19 data; therefore, we externally validated
it in (1) COVID-19 cohorts, to see how well the model transports
to patients it is being advertised for, and (2) non–COVID-19
cohorts, to see how well the model transports to patients similar
to those used to develop it.
We chose to investigate the performance of the model when
applied to patients with an outpatient or emergency department
(ED) visit with initial symptoms. We chose this approach
because it mimics the situation in which patients first seek
treatment or medical advice due to developing symptoms or
testing positive for COVID-19 (or influenza).
For the external validation using COVID-19 data, patients were
included in the target population if they satisfied the criteria
below:
• Presenting at an outpatient or ED visit with COVID-19
(COVID-19 was identified by a diagnosis code for
SARS-COV-2 or a positive test for SARS-COV-2 that was
recorded after January 1, 2020)
• Aged ≥18 years during the outpatient or ED visit
• ≥365 days of observation time in the data prior to the
outpatient or ED visit
• No diagnosis of influenza, influenza-like symptoms, or
pneumonia in the preceding 60 days (to ensure the index
date is the date of the most recent symptom of COVID-19)
The index date was defined as the date of the valid outpatient
or ED visit.
For the external validation using non–COVID-19 data (influenza
data), patients were included in the target population if they
satisfied the criteria below:
• Presenting at an outpatient or ED visit with a record of
influenza or influenza-like symptoms (ie, fever and either
cough, shortness of breath, myalgia, malaise, or fatigue)
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• Aged ≥18 years during the outpatient or ED visit
• ≥365 days of observation time in the data prior to the
outpatient/ED visit
• No diagnosis of influenza, influenza-like symptoms, or
pneumonia in the preceding 60 days (to ensure the index
date is the date of the most recent symptom of influenza)
The index date was defined the date of the valid outpatient or
ED visit.
Outcome
The outcome was hospitalization with pneumonia on the index
date (valid outpatient or ED visit) and within 30 days after index.
Multimedia Appendix 2 contains the definitions of pneumonia,
influenza, influenza-like symptoms, and COVID-19 used in
this study. The full details of the participant cohorts and the
outcomes used for validation can be found in the study package
[13].
Predictors
The predictors of the logistic regression version of the C-19
index are age in years, male sex, number of inpatient visits
during the prior 12 months, and indicator variables for various
Clinical Classifications Software Refined (CCSR) categories.
A table with the C-19 predictors and coefficients is presented
in Multimedia Appendix 3. The CCSR categories used were
pneumonia except that caused by tuberculosis, other and
ill-defined heart disease, heart failure, acute rheumatic heart
disease, coronary atherosclerosis and other heart disease,
pulmonary heart disease, chronic rheumatic heart disease,
diabetes mellitus with complication, diabetes mellitus without
complication, chronic obstructive pulmonary disease and
bronchiectasis, and other specified and unspecified lower
respiratory disease. Age interactions with each CCSR variable
were also included as predictors. Each CCSR category
corresponds to an aggregation of International Classification of
Disease, Tenth Revision (ICD-10) codes that belong to the
category.
In the development data, if a patient had an ICD-10 code that
was part of the CCSR “pneumonia except that caused by
tuberculosis” grouping during a specified time period prior to
index, their value for the predictor “pneumonia except that
caused by tuberculosis” was 1; otherwise, it was 0. This
assignment was repeated for each CCSR predictor. Data in the
OMOP-CDM do not use ICD-10 codes, but instead use
Systematized Nomenclature of Medicine (SNOMED) codes.
Therefore, to replicate the predictors in the OMOP-CDM data,
we needed to find the sets of SNOMED codes that corresponded
to each CCSR predictor. We accomplished this by finding the
SNOMED equivalent of each ICD-10 code in a CCSR category.
The SNOMED groupings per CCSR category used by the
OHDSI implementation of the C-19 are presented in Multimedia
Appendix 3.
Sample Size
We identified 41,381 patients with an outpatient or ED visit for
COVID-19 in 2020: 1985 patients from South Korea, 37,950
patients from Spain, and 1446 patients from the United States.
We also identified a total of 9,429,285 patients with an
outpatient or ED visit for influenza or influenza-like symptoms
in databases from six countries. The number of visits for
influenza or influenza-like symptoms per database ranged
between 2793 and 3,146,801.
Missing Data
The prediction models used a cohort design that included any
patient who satisfied the inclusion criteria. We did not exclude
patients who were lost to follow-up during the 30-day period
after the valid outpatient or ED visit.
Statistical Analysis Methods
The model performance was evaluated using the standard
discriminative metrics: area under the receiver operating
characteristic (AUROC) curve (equivalent to the C statistic)
and area under the precision recall curve (AUPRC). The latter
is a useful addition to the AUROC when assessing rare outcomes
[14]. An AUROC of 1 corresponds to a model that can always
assign a higher risk to patients who will experience the outcome
compared to those who will not. An AUROC of 0.5 corresponds
to a model that randomly guesses a patient’s risk. Precision is
defined as the number of true positives over the number of true
positives plus the number of false positives. Recall is defined
as the number of true positives over the number of true positives
plus the number of false negatives. The precision-recall curve
shows the tradeoff between precision and recall for different
thresholds. The AUPRC performance is relative to the rareness
of the outcome. An AUPRC greater than the percentage of the
population with the outcome indicates that the model is
discriminating, and the greater the value (closer to 1), the better
the discrimination. The AUPRC gives some insight into the
false positive rate; a low AUPRC value indicates that the model
will lead to many false positives. The calibration was determined
by creating deciles based on the predicted risk and plotting the
mean predicted risk versus the observed risk in each decile. If
a model is well calibrated, the mean predicted risk will be
approximately equal to the observed risk for each decile.
We followed the TRIPOD statement guidelines [11] for
reporting the model validation throughout this paper. For
transparency, an open source package for implementing the
model on any OMOP-CDM data is available on GitHub [13].
Development Versus Validation
The differences between the C-19 index model development
settings and the validation settings include a different target
population and different data sets. Our validation design settings
were chosen to mimic the situation in which a clinician needs
to decide whether to admit a patient with COVID-19.
Importantly, we validated the C-19 index model on patients
with COVID-19.
The C-19 index was developed using a cohort design that
entered adult patients into the cohort on September 30, 2016,
and predicted whether they would be hospitalized for pneumonia
or proxies (influenza, acute bronchitis, or other specified upper
respiratory infections) in the following 3 months. Patients were
required to have data for 6 or more months, and patients who
left the database within 3 months of index and whose deaths
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were not recorded were excluded. In our external validation,
we used a cohort design but entered adult patients into the cohort
when they had an initial outpatient/ED visit for influenza (or
COVID-19) rather than a fixed date; also, we predicted
hospitalization due to pneumonia in 30 days rather than 3
months. We excluded patients with influenza or pneumonia
within the 60 days prior to index to restrict the data to initial
visits. This mimics the situation during the COVID-19 pandemic
in which clinicians need to decide whether to hospitalize a
patient initially presenting with COVID-19. We required 12
months of prior observation and did not exclude patients who
left the database within 3 months of index.
The C-19 index was developed using a subset of patients from
the MDCR database prior to the pandemic. This is a US claims
database containing patients aged 65 years or older. In this study,
we were able to externally evaluate the C-19 index model on
COVID-19 data, including adult patients under 65 years of age,
from South Korea, Spain, and the United States.
Results
Web-Based Results
The complete results of our analysis are available as an
interactive app [15].
The characteristics of the MDCR data (same data source as the
development data but different patient subset) and the HIRA,
SIDIAP, and VA data (patients with COVID-19) are displayed
in Table 1. The characteristics for all data sets used in the study
are available in Multimedia Appendix 4.
Table 1. Characteristics of patients at baseline in MDCR (database similar to the development data) and the data sets with COVID-19 data.




0.220.32——d0.681.380.350.58Mean number of inpatient visits in prior 365 days
8095435946564552Male sex (%)
Fraction of patients with a history of each condition (not including index)
————0000Acute rheumatic heart disease
0.210.270.030.060.210.380.250.43Chronic obstructive pulmonary disease and
bronchiectasis
————000.020.03Chronic rheumatic heart disease
0.130.170.010.020.090.210.150.19Coronary atherosclerosis and other heart disease
0.240.380.010.030.130.310.180.24Diabetes mellitus with complication
0.320.500.050.130.200.430.320.38Diabetes mellitus without complication
0.120.230.010.020.070.200.200.37Heart failure
0.060.110.010.010.010.020.150.25Other and ill-defined heart disease
0.450.580.380.430.880.920.590.73Other specified and unspecified lower respiratory
disease
0.140.200.060.060.150.310.200.39Pneumonia (except that caused by tuberculosis)
————0.000.000.040.09Pulmonary heart disease
aHIRA: Health Insurance Review and Assessment.
bSIDIAP: Information System for Research in Primary Care.
cVA: Department of Veterans Affairs.
d—: Data not included due to a low cell count.
Model Performance
When C-19 was transported to patients with COVID-19, it
achieved AUROCs between 0.36 and 0.56; full details are
provided in Table 2. The AUROC and calibration plots are
presented in Figure 1. The internal discriminative performance
of the C-19 index was an AUROC of 0.73. When we validated
the model on patients in the MDCR database (patients aged ≥65
years with supplemental Medicare coverage), but with our target
population consisting of symptomatic influenza patients, the
performance was 0.65, a substantial drop from the development
performance of 0.73. The AUROC performance when externally
validated across other databases containing influenza patients
ranged between 0.40 and 0.68. Full results are presented in
Table 3, and the AUROC and calibration plots are presented in
Multimedia Appendix 5. As a sensitivity analysis, we also
validated the C-19 index on a target population consisting of
patients who had COVID-19 or symptoms of the disease in
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2020; the results were similar and are presented in Table S2 in Multimedia Appendix 1.
Table 2. External validation of the COVID-19 vulnerability index model on COVID-19 data. The target cohort was patients with an outpatient or
emergency department visit with a COVID-19–positive record in 2020 and no symptoms in the prior 60 days.




aAUROC: area under the receiver operating characteristic curve.
bThe 95% CI is reported when the outcome count is <1000.
cAUPRC: area under the precision recall curve.
dHIRA: Health Insurance Review and Assessment.
eSIDIAP: Information System for Research in Primary Care.
fVA: Department of Veterans Affairs.
Figure 1. Receiver operating characteristic and calibration plots of the COVID-19 vulnerability index model for the three data sets with sufficient and
suitable COVID-19 data. HIRA: Health Insurance Review and Assessment; SIDIAP: Information System for Research in Primary Care; VA-OMOP:
Department of Veterans Affairs– Observational Medical Outcomes Partnership.
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Table 3. External validation of the COVID-19 vulnerability index model on influenza patient data (non–COVID-19 data).
AUPRCcAUROCa (95% CI)bOutcome size, n (%)Target population size, nDatabase
0.160.6832,987 (6.15)536,806Medicaid
0.0040.58 (0.55-0.60)728 (0.06)1,276,478Japanese Medical Data Center
0.210.6531,059 (12.47)248,989Medicare supplemental
0.040.5833,824 (1.07)3,146,801Commercial Claims and Encounters
0.070.6234,229 (2.07)1,654,157Optum EHRd
0.170.67105,030 (5.04)2,082,277ClinFormatics
0.040.52 (0.41-0.63)49 (1.58)3105Ajou University School of Medicine
0.060.63 (0.58-0.69)147 (2.34)6272Tufts Medical Center Research Data Warehouse
0.030.59 (0.45-0.72)29 (1.04)2793Australia Electronic Practice–Based Research Network
0.100.641121 (5.10)27,356Columbia University Irving Medical Center
0.000.40 (0.26-0.54)22 (0.08)29,132Integrated Primary Care Information
0.000.49 (0.45-0.52)512 (0.12)415,119SIDIAPe
aAUROC: area under the receiver operating characteristic curve.
bThe 95% CI is reported when the outcome count is <1000.
cAUPRC: area under the precision recall curve.
dEHR: electronic health record.
eSIDIAP: Information System for Research in Primary Care.
Discussion
The C-19 index is available on the web as a tool to predict
severity in patients with COVID-19; however, it lacks validation
for this population. Our validation across three data sets with
sufficient COVID-19 data showed poor discriminative
performance (AUROCs <0.6) and calibration. We observed
similarly poor performance when the model was validated across
12 data sets with influenza patients, with the best AUROCs
<0.70.
Interpretation
The key finding of this study is the performance of the C-19
index model when transported to patients with COVID-19. The
model performance was poor (AUROCs 0.36-0.56) across the
COVID-19 data sets. The performance was worse than random
guessing in the SIDIAP data, which is consistent with the poor
performance seen when the model was applied to European
patients with influenza. The calibration plots show that the C-19
index consistently underestimated risk in the patients with
COVID-19.
The data sets used to perform the validation had very different
patient populations. MDCR had the oldest patient population,
and many patients in this data set had comorbidities. Compared
to MDCR, the CCAE and JMDC data sets presented healthier
and younger patients (mean age approximately 40 years) in the
target population. Although the MDCD data set contained
younger patients, these patients often had comorbidities (ie,
20% these patients had chronic obstructive pulmonary disease,
11% had heart failure, and 17% had a history of pneumonia).
The rate of hospitalization ranged greatly across the data sets,
with values between 0.1% (JMDC) and 12.4% (MDCR). The
rate of the outcome in the data set used to develop the C-19
index was 0.23%, much lower than that in the MDCR data set
used to validate the model in this study. This is because our
study was restricted to patients at the point they had an
outpatient or ED visit due to influenza or COVID-19. Although
five data sets contained patients with COVID-19, only four
(VA, HIRA, SIDIAP, and CUIMC) contained sufficient data
for external validation. The result of the C-19 index model when
applied to patients with COVID-19 in CUIMC was poor, with
an AUROC <0.5; however, this data set consisted mostly of
hospitalized patients and therefore did not seem to be suitable
for validating a model that predicts hospitalizations.
We chose a target population of symptomatic patients because
this resembles the situation in which COVID-19 prediction
models may be clinically implemented during the pandemic:
clinicians would not be likely to admit asymptomatic patients.
This suggests that the internal C-19 AUROC estimate, which
was evaluated within the general population rather than among
people with symptoms, may be optimistic compared to its use
in a realistic setting due to the inclusion of many healthy patients
in the model development data. When applied to predict
hospitalization in influenza patients across US data, the
discriminative performance ranged between 0.58 and 0.68. The
performance was worse on the CCAE data set with younger
patients, likely because age is a key predictor in the model.
When the C-19 index was transported across non-US data sets,
the discrimination was poor to reasonable in the Australian and
Asian data (0.52-0.64) and poor in the European data (0.4-0.49).
The European data were extracted from general practice settings,
but the C-19 index model was developed using US claims data.
Given the differences in clinical settings, it is not surprising that
the performance was poor. This finding highlights that models
often may not transport to different health care settings. The
AUROC of 0.36 when the C-19 index model was validated in
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SIDIAP was worse than random guessing, and inverting the
predicted risk would lead to an AUROC of 0.64. This may be
a result of the C-19 including age interaction terms, which
resulted in a negative age coefficient. Table 1 shows that in
SIDIAP, the model’s age-interacting comorbidities are not
recorded as often as in the other databases. As a result, younger
patients may have been assigned higher risks than older patients
in SIDIAP.
The calibration was poor when applying the C-19 to COVID-19
data. This is not unexpected, as it is known that patients with
COVID-19 have a higher risk of hospitalization due to
pneumonia than the general COVID-19–free population. The
calibration could likely be improved by performing recalibration
using a sample of data from patients with COVID-19.
Implications
The results provide extensive insight into the performance of
the logistic regression C-19 index when used for COVID-19
data. The external validation uncovered that the logistic
regression C-19 index model is unreliable when predicting
hospitalization risk for patients with COVID-19. Given this
result, we do not recommend using the logistic regression C-19
index to aid decision-making during the COVID-19 pandemic.
The model did not appear to transport to patients with
COVID-19, highlighting the importance of externally validating
models, especially models whose target population differs from
the development population.
There are numerous potential reasons why the logistic regression
C-19 index model failed to predict hospitalization due to
pneumonia in the investigated patients with COVID-19. The
first reason may be that the model was developed on patients
aged 65 years or older but was applied to patients aged 18 or
older. Age had a negative coefficient in the model, which may
have caused issues when the model was applied to younger
patients. A second reason may be due to incorrect phenotyping
of the predictors. We matched the SNOMED codes to the CCSR
ICD-10 codes provided; however, the predictors may require
database-specific phenotypes due to coding differences across
data sets and health care settings. This may explain the poor
performance in the European data sets, which were obtained
from databases that may record entries differently than those in
the United States. A third reason is the study design. The C-19
index was developed to predict hospitalization from a set date
in 2016; however, we validated it in a target cohort of
symptomatic patients with an outpatient or ED visit, as this
more closely matches the clinical use case of the model.
Therefore, we were likely to have a sicker population, in which
discrimination may have been more difficult. A fourth potential
reason is that the C-19 index model was developed using data
prior to 2017 but was validated on data from 2020: temporal
changes and concept drift may have negatively impacted the
performance. Although we do not know the reason for the
unreliability of the C-19 index model on patients with
COVID-19, we were able to quantify it by large-scale external
validation across a network of data sets. In future work, it would
be beneficial to develop techniques that can identify reasons
for poor external validation performance, as this may inform
new best practices for model development.
This study highlights the importance of performing extensive
external validation across different settings. During times of
uncertainty, such as pandemics, medical staff who are under
pressure to make important decisions could benefit from
implementing vetted prediction models. However, it is important
to gain an unbiased and reliable evaluation of a model’s
performance across numerous patient populations before the
model is used. Internal validation can often be biased (eg, the
population used to develop the model does not match the
intended target population) and can provide optimistic
performance estimates (eg, a poor design or small data set may
result in overestimated discriminative performance). The
approach used by the OHDSI collaboration enables efficient
external validation of models across multiple data sets, and this
is a valuable resource when urgency is required.
Limitations
A common issue when using observational health care data,
especially across a network of databases, is the difficulty in
developing phenotypes that are valid on all data sets. In this
study, we used predictor definitions given by the researchers
who developed the model. However, these definitions may not
transport across all the data sets and may account for some of
the decrease in performance. We were also limited to validating
the less complex C-19 index model due to the large number of
variables and lack of transparency for the more complex models.
The C-19 index model used in this paper to demonstrate the
importance of external validation may have limited use for
medical decision-making. Other COVID-19 models, such as
those including physiological measurements, may be making
more clinical impact. However, we choose the C-19 index model
because it was available early in the pandemic and was being
advertised to the public as a useful tool while being reported in
a preprint paper with no formal peer review.
Conclusions
We have demonstrated the importance of implementing external
validation in multiple data sets to determine the reliability of
prediction models. We picked a newly developed model, the
C-19 index, that aimed to predict which patients with COVID-19
are at risk of severe complications due to SARS-CoV-2. The
model reported an internal AUC of 0.73 but was deemed to
have a high risk of potential bias [2]. The C-19 index addresses
an important issue that could have greatly aided decision-making
during the COVID-19 pandemic; however, its performance in
patients with COVID-19 was unknown. Our results show that
the C-19 index performs poorly when applied to newly
diagnosed patients with COVID-19 in Asia, Europe, and the
United States. Overall, we suggest that the model currently only
be used to predict hospitalization due to pneumonia in older
patients in the United States. The results of this study
demonstrate that internal validation performance should be
considered optimistic estimates and that a prediction model
requires validation across multiple data sets in the target
population where it will be used (or a close proxy) before it
should be trusted.
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